Subscribe

Treatment with a Novel HDAC6 Inhibitor plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Conference Correspondent - Conference Correspondent, ASH 2016 - Multiple Myeloma

This phase 1a/1b study evaluated safety, tolerability, and preliminary efficacy of ACY-241 monotherapy in combination with pomalidomide (Pom) and dexamethasone (Dex); results were presented at the ASH 2016 Annual Meeting. Patients were treated with a single cycle of ACY-241 monotherapy followed by ACY-241 in combination with Pom (4 mg) and low-dose Dex in patients with relapsed or relapsed/refractory multiple myeloma. Cohorts of 3 patients received ACY-241 once daily as monotherapy (180, 360, and 480 mg) on days 1 to 21 of a 28-day cycle. Patients tolerating this initial cycle continued to cycle 2 of combination therapy with ACY-241/Pom/Dex.

A total of 63 patients have enrolled in the study, with a median age of 62 years. Median number of prior regimens was 2 (1-10). Seventy-six percent of patients were refractory to Len and 40% to both bortezomib and Len. Toxicities were primarily grade 1 or 2. In patients who received a dose of 360 mg of ACY-241 in combination with Pom and Dex, grade 3/4 toxicities included neutropenia (14 patients, 35%), anemia (10 patients, 25%), thrombocytopenia (6 patients, 15%), back pain (4 patients, 10%), and leukopenia (4 patients, 10%). Pharmacokinetic results showed a dose-linear increase in exposure with increasing dose, no accumulation, and no drug–drug interaction with Pom and Dex. Efficacy data for combination treatment (N = 56 evaluable patients, all refractory to last treatment regimen) showed the following: 7 very good partial responses, 19 partial responses, 7 minimal responses, 18 with stable disease, and 5 with progressive disease. Median duration of response was 9.2 months, and median progression-free survival was 6.5 months.

Investigators concluded that ACY-241 was well-tolerated in monotherapy at a dose of 480 mg daily and in combination with Pom/Dex at a dose of 360 mg daily. Initial response data are also promising; researchers anticipate that efficacy may compare favorably to the combination of Pom and Dex, but further study is required.

Niesvizky R, et al. ASH 2016. Abstract 3307.

Related Items
Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Improved Quality of Life in Adults with Acute Bacterial Skin and Skin Structure Infections with Omadacycline or Linezolid Therapy
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Integrated Safety Summary of Omadacycline, A Novel Aminomethylcycline Antibiotic
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Last modified: August 30, 2021
Copyright © Engage Healthcare Communications, LLC. All rights reserved.